Successful treatment of severe, treatment resistant GHB withdrawal through thiopental-coma

References

• Van Laar MW, Van Gestel B, Cruts P. 2019. Netherlands national drug monitor 2018. Utrecht, The Netherlands: Trimbos Institute.
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2019: Trends and Developments. https://data.europa.eu/doi/10.2810/191370. Published 2019. Accessed November 21, 2019.
   Google Scholar
• Wisselink DJ, Kuipers WG, Mol A. Key figures addiction care 2015 National Alcohol and Drugs Information System. Houten: LADIS (National Alcohol and Drugs Information System); 2016. ISBN/EAN: 9780-90-5726-059-9
   Google Scholar
• Kamal RM, van Noorden MS, Wannet W, Beurmanjer H, Dijkstra BAG, Schellekens A. Pharmacological treatment in γ-hydroxybutyrate (GHB) and γ-butyrolactone (GBL) dependence: detoxification and relapse prevention. CNS Drugs. 2017;31(1):51–64.
   PubMed Web of Science ®Google Scholar
• Galicia M, Nogue S, Miro O. Liquid ecstasy intoxication: clinical features of 505 consecutive emergency department patients. Emerg Med J. 2011;28(6):462–466.
   PubMed Web of Science ®Google Scholar
• Galicia M, Dargan PI, Dines AM, et al. Clinical relevance of ethanol coingestion in patients with GHB/GBL intoxication. Toxicol Lett. 2019;314:37–42.
   PubMed Web of Science ®Google Scholar
• Corkery JM, Loi B, Claridge H, et al. Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD; BDO): a literature review with a focus on UK fatalities related to non-medical use. Neurosci Biobehav Rev. 2015;53:52–78.
   PubMed Web of Science ®Google Scholar
• Kamal RM, Dijkstra BAG, Loonen AJ, De Jong CAJ. The effect of co-occurring substance use on gamma-hydroxybutyric acid withdrawal syndrome. J Addict Med. 2016;10(4):229–235.
   PubMed Web of Science ®Google Scholar
• McDonough M, Kennedy N, Glasper A, Bearn J. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend. 2004;75(1):3–9.
   PubMed Web of Science ®Google Scholar
• Adis Medical Writers. Treat γ-hydroxybutyrate (GHB) and γ-butyrolactone (GBL) dependence with benzodiazepines first, then with other approaches if benzodiazepine-resistant. Drugs Ther Perspect. 2017;33(11):523–528.
   Google Scholar
• Kamal R, Dijkstra BAG, van Iwaarden JA, van Noorden MS, de Jong CAJ. Practice-Based Recommendations for the Detoxification of Patients with GHB Abuse Disorders (protocol in Dutch). Amersfoort, The Netherlands: Resultaten Scoren; 2013.
   Google Scholar
• Beurmanjer H, Verbrugge CAG, Schrijen S., Schellekens AFA, DeJong CAJ, Dijkstra BAG Behandeling van GHB afhankelijkheid na detoxificatie; Eindrapportage NISPA GHB Monitor 2.0, Nijmegen: NISPA; 2016. ISBN/EAN: 978-90-819800-6-7
   Google Scholar
• Dijkstra BAG, Kamal R, van Noorden MS, de Haan H, Loonen AJM, De Jong CAJ. Detoxification with titration and tapering in gamma-hydroxybutyrate (GHB) dependent patients: the Dutch GHB monitor project. Drug Alcohol Depend. 2017;170:164–173.
   PubMed Web of Science ®Google Scholar
• Ghio L, Cervetti A, Respino M, Belvederi Murri M, Amore M. Management and treatment of gamma butyrolactone withdrawal syndrome: a case report and review. J Psychiatr Pract. 2014;20(4):294–300.
   PubMed Web of Science ®Google Scholar
• Sivilotti ML, Burns MJ, Aaron CK, Greenberg MJ. Pentobarbital for severe gamma-butyrolactone withdrawal. Ann Emerg Med. 2001;38(6):660–665.
   PubMed Web of Science ®Google Scholar
• Mirijello A, D’Angelo C, Ferrulli A, et al. Identification and management of alcohol withdrawal syndrome. Drugs. 2015;75(4):353–365.
   PubMed Web of Science ®Google Scholar
• Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med. 2001;29(7):1370–1379.
   PubMed Web of Science ®Google Scholar
• Beurmanjer H, Kamal RM, de Jong CAJ, Dijkstra BAG, Schellekens AFA. Baclofen to prevent relapse in gamma-hydroxybutyrate (GHB)-dependent patients: a multicentre, open-label, non-randomized, controlled trial. CNS Drugs. 2018;32(5):437–442.
   PubMed Web of Science ®Google Scholar
• Mannucci C, Pichini S, Spagnolo EV, et al. Sodium oxybate therapy for alcohol withdrawal syndrome and keeping of alcohol abstinence. Curr Drug Metab. 2018;19(13):1056–1064.
   PubMed Web of Science ®Google Scholar
• Weaver MF. Prescription sedative misuse and abuse. Yale J Biol Med. 2015;88(3):247–256.
   PubMedGoogle Scholar
• Modesto-Lowe V, Huard J, Conrad C. Alcohol withdrawal kindling: is there a role for anticonvulsants? Psychiatry. 2005;2(5):25–31.
   PubMedGoogle Scholar
• Allison C, Pratt JA. Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence. Pharmacol Ther. 2003;98(2):171–195.
   PubMed Web of Science ®Google Scholar
• Raposo Pereira F, McMaster MTB, Polderman N, de Vries YDAT, van den Brink W, van Wingen GA. Adverse effects of GHB-induced coma on long-term memory and related brain function. Drug Alcohol Depend. 2018;190:29–36.
   PubMed Web of Science ®Google Scholar
• Raposo Pereira F, McMaster MTB, Polderman N, de Vries YDAT, van den Brink W, van Wingen GA. Effect of GHB-use and GHB-induced comas on dorsolateral prefrontal cortex functioning in humans. Neuroimage Clin. 2018;20:923–930.
   PubMed Web of Science ®Google Scholar
• Rosenberg MH, Deerfield LJ, Baruch EM. Two cases of severe gamma-hydroxybutyrate withdrawal delirium on a psychiatric unit: recommendations for management. Am J Drug Alcohol Abuse. 2003;29(2):487–496.
   PubMed Web of Science ®Google Scholar
• Schneir AB, Ly BT, Clark RF. A case of withdrawal from the GHB precursors gamma-butyrolactone and 1,4-butanediol. J Emerg Med. 2001;21(1):31–33.
   PubMed Web of Science ®Google Scholar
• Galloway GP, Frederick SL, Staggers FE, Gonzales M, Stalcup SA, Smith DE. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction. 1997;92(1):89–96.
   PubMed Web of Science ®Google Scholar
• Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3–23.
   PubMed Web of Science ®Google Scholar
• Huynh F, Mabasa VH, Ensom MHH. A critical review: does thiopental continuous infusion warrant therapeutic drug monitoring in the critical care population? Ther Drug Monit. 2009;31(2):153–169.
   PubMed Web of Science ®Google Scholar
• Nardou R, Yamamoto S, Bhar A, Burnashev N, Ben-Ari Y, Khalilov I. Phenobarbital but Not Diazepam Reduces AMPA/kainate Receptor Mediated Currents and Exerts Opposite Actions on Initial Seizures in the Neonatal Rat Hippocampus. Front Cell Neurosci. 2011;5:16.
   PubMed Web of Science ®Google Scholar
• Nisavic M, Nejad SH, Isenberg BM, et al. Use of phenobarbital in alcohol withdrawal management - a retrospective comparison study of phenobarbital and benzodiazepines for acute alcohol withdrawal management in general medical patients. Psychosomatics. 2019;60(5):458–467.
   PubMed Web of Science ®Google Scholar
• Martin K, Katz A. The role of barbiturates for alcohol withdrawal syndrome. Psychosomatics. 2016;57(4):341–347.
   PubMed Web of Science ®Google Scholar